A Phase IIIb, Controlled, Open Label, Single-Center, Persistency, Extension Study in Chinese Children After a 2+1 Dose Series of Either CRM197-Conjugate Haemophilus Influenzae Type b Vaccine or Tetanus Toxoid-Conjugate Haemophilus Influenzae Type b Vaccine

Trial Profile

A Phase IIIb, Controlled, Open Label, Single-Center, Persistency, Extension Study in Chinese Children After a 2+1 Dose Series of Either CRM197-Conjugate Haemophilus Influenzae Type b Vaccine or Tetanus Toxoid-Conjugate Haemophilus Influenzae Type b Vaccine

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2015

At a glance

  • Drugs TAK 816 (Primary) ; Hib vaccine conjugate
  • Indications Gram-negative infections; Haemophilus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Novartis
  • Most Recent Events

    • 22 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 06 Oct 2014 Planned End Date changed from 1 Sep 2014 to 1 Dec 2014, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top